Ascites Clinical Trial
— OTMA-RIIOfficial title:
Local Modulated Electro-Hyperthermia in Combination With Traditional Chinese Medicine Versus Intraperitoneal Chemoinfusion in Treatment of Peritoneal Carcinomatosis With Malignant Ascites: A Phase II Randomized Trial
This trial studies efficacy and safety of combination of modulated electro-hyperthermia (mEHT) with Traditional Chinese Medicine (TCM) in treatment of peritoneal carcinomatosis with malignant ascites versus standard chemoinfusion (CDDP+5FU).
Status | Completed |
Enrollment | 260 |
Est. completion date | December 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Pathologically confirmed PC with malignant ascites. - Karnofsky Performance Status (KPS) score =60%. - Normal function of bone marrow. - Predicted survival time >1 month. - Written informed consent. Exclusion Criteria: - Surgery within 3 weeks or not full recovery of postoperative suture. - Active bleeding or vascular occlusion in the mEHT treatment area. - Emotional instability. - Impossibility to place the patient into the mEHT machine. - Metallic implants or replacements in the treatment area. - Electronic implanted devices anywhere. - Missing or damaged heat-sense nerves or other field-sensitive issues in the treatment area. - Very low white blood cell count (<1.5×10(9)/L), agranulocytosis (<0.5×10(9)/L) or severe anemia. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Clifford Hospital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Galenic Research Institute Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Reaponse Rate (ORR) | Complete Remission and Partial Remission (CR + PR) | 8 weeks after start of treatment (4 weeks on completion of treatment) | No |
Secondary | Adverse Events Rate (AER) | During 4 weeks of treatment course and 4 weeks after treatment | Yes | |
Secondary | Quality of Life (QoL) | Karnofsky Performance Score Improvement Rate (KPS IR) | 8 weeks after start of treatment (4 weeks on completion of treatment) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02891642 -
Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
|
||
Recruiting |
NCT00239096 -
Prevention of Decompensation in Liver Cirrhosis
|
Phase 4 | |
Active, not recruiting |
NCT03973866 -
Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)
|
N/A | |
Terminated |
NCT01455246 -
Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
|
Phase 2/Phase 3 | |
Completed |
NCT01349348 -
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
|
Phase 3 | |
Completed |
NCT01578226 -
Procalcitonin in Cirrhotic Patients at High Risk for Sepsis
|
N/A | |
Terminated |
NCT00548366 -
Sodium Restriction in the Management of Cirrhotic Ascites
|
Phase 4 | |
Recruiting |
NCT05025878 -
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
|
||
Completed |
NCT03327688 -
Point-of-care Ultrasound in Finland
|
N/A | |
Not yet recruiting |
NCT04550091 -
Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
|
||
Not yet recruiting |
NCT01716611 -
Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
|
Phase 4 | |
Completed |
NCT01769040 -
Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
|
Phase 4 | |
Recruiting |
NCT05511766 -
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05700708 -
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
|
||
Completed |
NCT05013502 -
Empagliflozin in Diuretic Refractory Ascites
|
Phase 1 | |
Not yet recruiting |
NCT06436807 -
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
|
||
Completed |
NCT03263598 -
Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites
|
||
Completed |
NCT00907673 -
The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure
|
N/A | |
Suspended |
NCT00511394 -
Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis
|
N/A | |
Terminated |
NCT00796861 -
Trial of Sunitinib for Refractory Malignant Ascites
|
Phase 2 |